Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACRX

Acelrx Pharmaceuticals Inc

Dec 07 • 04:00PM ET

0.7632

Dollar change -0.0618
Percentage change -7.49	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.23	Insider Own	5.30%	Shs Outstand	16.95M	Perf Week	3.84%
Market Cap	12.94M	Forward P/E	-	EPS next Y	-0.71	Insider Trans	-0.77%	Shs Float	16.05M	Perf Month	46.57%
Income	-21.36M	PEG	-	EPS next Q	-0.16	Inst Own	36.71%	Short Float / Ratio	4.68% / 3.54	Perf Quarter	-12.11%
Sales	0.62M	P/S	20.86	EPS this Y	-120.28%	Inst Trans	2.89%	Short Interest	0.75M	Perf Half Y	-31.24%
Book/sh	1.08	P/B	0.71	EPS next Y	38.36%	ROA	-37.07%	Target Price	4.62	Perf Year	-62.03%
Cash/sh	0.79	P/C	0.97	EPS next 5Y	-	ROE	-57.87%	52W Range	0.43 - 2.78	Perf YTD	-66.23%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-116.70%	52W High	-72.55%	Beta	0.50
Dividend %	-	Quick Ratio	4.04	Sales past 5Y	-3.04%	Gross Margin	-22.73%	52W Low	79.58%	ATR	0.07
Employees	19	Current Ratio	4.04	Sales Q/Q	-76.92%	Oper. Margin	-3214.15%	RSI (14)	62.09	Volatility	7.64% 11.55%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	91.38%	Profit Margin	-3434.73%	Rel Volume	0.58	Prev Close	0.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 08 AMC	Payout	0.00%	Avg Volume	212.41K	Price	0.76
Recom	1.00	SMA20	22.79%	SMA50	28.41%	SMA200	-10.37%	Volume	123,234	Change	-7.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-20	Downgrade	Credit Suisse	Neutral → Underperform
Nov-11-19	Downgrade	Credit Suisse	Outperform → Neutral	$7 → $2
Aug-05-19	Resumed	Credit Suisse	Outperform
Jul-10-19	Resumed	Credit Suisse	Outperform
Apr-24-19	Resumed	B. Riley FBR	Buy	$6.50
Feb-15-19	Initiated	Credit Suisse	Outperform	$7
Oct-23-18	Initiated	B. Riley FBR	Buy	$9
Oct-13-17	Reiterated	RBC Capital Mkts	Outperform	$6 → $5
Oct-13-17	Downgrade	Jefferies	Buy → Hold
Jul-14-17	Resumed	Jefferies	Buy	$7
Sep-15-16	Reiterated	ROTH Capital	Buy	$11.25 → $15
Aug-05-16	Downgrade	Stifel	Buy → Hold
Oct-30-15	Upgrade	Jefferies	Hold → Buy
Oct-05-15	Reiterated	ROTH Capital	Buy	$8.50 → $10.50
Sep-02-15	Initiated	H.C. Wainwright	Buy	$8.50
Jul-10-15	Resumed	ROTH Capital	Buy	$7.50
May-06-15	Reiterated	Mizuho	Neutral	$5.50 → $3
May-05-15	Reiterated	RBC Capital Mkts	Outperform	$8 → $7
Mar-10-15	Reiterated	RBC Capital Mkts	Outperform	$12 → $8
Mar-09-15	Downgrade	Mizuho	Buy → Neutral	$14 → $5.59

Show Previous Ratings

Nov-09-23 11:06AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.34%
Nov-08-23 05:22PM	AcelRx Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-07-23 04:05PM	AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study (PR Newswire)
Oct-26-23 04:30PM	AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023 (PR Newswire)
08:30AM	Loading…
Oct-03-23 08:30AM	AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study (PR Newswire)
Sep-12-23 01:02PM	Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc (GuruFocus.com) +12.80%
Sep-06-23 08:30AM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire)
Aug-22-23 05:30PM	What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock (Zacks)
Aug-13-23 05:33AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:07AM	Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:30PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.46%
04:20PM	AcelRx Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-23 04:05PM	AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023 (PR Newswire)
08:00AM	Loading…
Jul-21-23 08:00AM	AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jul-18-23 08:00AM	AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (PR Newswire)
May-10-23 06:25PM	AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1 (Zacks)
05:18PM	AcelRx Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
04:05PM	AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
May-04-23 10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
May-03-23 10:00AM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-27-23 04:05PM	AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023 (PR Newswire)
Apr-05-23 08:30AM	AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire)
Apr-04-23 12:30PM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-30-23 06:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-21-23 04:05PM	AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023 (PR Newswire) +18.10%
Mar-14-23 08:30AM	AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals (PR Newswire) -21.05%
08:30AM	Loading…
Mar-01-23 08:30AM	AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures (PR Newswire) -7.04%
Dec-29-22 06:02AM	AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript (Insider Monkey) +7.58%
Dec-27-22 08:30AM	AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
Dec-19-22 08:17AM	10 Cheapest Stocks With Biggest Upside (Insider Monkey) -7.95%
Dec-08-22 08:30AM	AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine (PR Newswire)
Nov-17-22 05:17AM	AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-14-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +17.96%
04:01PM	AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-03-22 08:30AM	AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022 (PR Newswire)
Oct-31-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022 (PR Newswire)
Oct-27-22 08:30AM	AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant (PR Newswire) -12.47%
Oct-26-22 08:30AM	AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022 (PR Newswire) -12.81%
Oct-25-22 04:42PM	AcelRx Pharmaceuticals Announces Reverse Stock Split (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences (PR Newswire)
Sep-06-22 04:30PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference (PR Newswire) -7.32%
Aug-25-22 08:30AM	AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Aug-11-22 05:35PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +33.02%
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 (PR Newswire)
Aug-10-22 08:30AM	AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting (PR Newswire)
Jul-28-22 04:50PM	AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022 (PR Newswire)
Jul-08-22 06:28AM	AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years (Simply Wall St.) -13.71%
May-20-22 12:49PM	AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference (PR Newswire) -11.83%
May-19-22 11:56AM	Why AcelRx Pharma Shares Are Trading Higher Today? (Benzinga) +27.63%
08:30AM	AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA® (PR Newswire)
May-16-22 08:45AM	AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-12-22 05:35PM	Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-10-22 05:35PM	Organogenesis (ORGO) Q1 Earnings Lag Estimates (Zacks)
08:30AM	AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia (PR Newswire)
May-09-22 07:30PM	AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022 (PR Newswire) -13.47%
Apr-27-22 08:00AM	AcelRx Hosting Key Opinion Leader Webinar on Niyad Nafamostat Program (GlobeNewswire)
Apr-25-22 08:30AM	Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022 (PR Newswire)
Apr-21-22 08:30AM	AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022 (PR Newswire) -8.00%
Mar-31-22 04:10PM	AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures (PR Newswire)
Mar-29-22 01:08PM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit (PR Newswire) -6.87%
Mar-10-22 05:15PM	AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results (PR Newswire)
Mar-03-22 04:05PM	AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 (PR Newswire) -7.14%
Feb-01-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures (PR Newswire)
Jan-31-22 04:24AM	When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven? (Simply Wall St.) +11.77%
Jan-27-22 01:38PM	Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ... (GuruFocus.com) -8.64%
08:30AM	AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures (PR Newswire)
Jan-12-22 08:30AM	AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery (PR Newswire) -5.53%
Jan-10-22 08:30AM	AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics (PR Newswire)
Dec-23-21 08:05AM	Femasys Inc. to Participate in Upcoming January Investor Conferences (GlobeNewswire)
Dec-15-21 08:30AM	AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery (PR Newswire)
Dec-01-21 07:12PM	Penny Stocks to Buy Using Technical Analysis for December 2021 (Investopedia)
Nov-23-21 05:09PM	AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors (PR Newswire) -5.22%
Nov-15-21 06:45AM	AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering (PR Newswire) -6.08%
06:00AM	AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-10-21 08:30AM	AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021 (PR Newswire)
Nov-02-21 06:22AM	Investors in AcelRx Pharmaceuticals (NASDAQ:ACRX) have unfortunately lost 80% over the last three years (Simply Wall St.)
Oct-28-21 03:06PM	AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-21-21 09:32PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio, Danimer Scientific, AcelRX, and Piedmont Lithium on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-04-21 07:30AM	Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors (GlobeNewswire)
Sep-10-21 03:19PM	AcelRx Pharmaceuticals to Participate in Two September Investor Conferences (PR Newswire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)
08:30AM	Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event (PR Newswire)
Aug-26-21 08:30AM	Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event (PR Newswire)
Aug-19-21 07:07AM	21 Stocks Moving in Thursday's Pre-Market Session (Benzinga)
Aug-16-21 05:25PM	AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results (PR Newswire)
Aug-12-21 04:01PM	Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm (Newsfile)
Aug-09-21 04:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX (PR Newswire)
01:30PM	ACRX Last Few Hours to Deadline: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Are Encouraged to Contact Bronstein, Gewirtz & Grossman, LLC (ACCESSWIRE)
10:16AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
10:00AM	ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021 (Newsfile)
09:25AM	ACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX (Newsfile)
08:30AM	AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021 (PR Newswire)

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Angotti Vincent J.	Chief Executive Officer	Sep 11	Buy	0.80	10,000	7,950	91,805	Sep 11 07:13 PM
Palmer Pamela P	Chief Medical Officer	Aug 25	Sale	1.09	7,442	8,104	30,753	Aug 25 04:45 PM
Palmer Pamela P	Chief Medical Officer	Aug 24	Sale	1.17	9,514	11,131	38,195	Aug 25 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACRX

Acelrx Pharmaceuticals Inc

Upgrade your FINVIZ experience